LONDON, July 13, 2022 (GLOBE NEWSWIRE) -- The "Type 2 Diabetes (Metabolic Disorder) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update" report offered by Globaldata provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.
Type 2 Diabetes Pipeline Drugs Market - Competitive Landscape
Number of Type 2 Diabetes Pipeline Products, by Leading Companies
To know more about leading type 2 diabetes pipeline product companies, download a sample report
Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men's health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company that discovers, develops, and manufactures innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company's portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. With subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East, and Australia, the company markets its products in several countries. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Merck & Co Inc (Merck) is a biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune disorders, infectious, respiratory and women's diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
Other Leading Companies in the Type 2 Diabetes Pipeline Drugs Market
Type 2 Diabetes Therapeutics Assessment by Targets
Number of Type 2 Diabetes Pipeline Products, by Targets
For more target insights on type 2 diabetes pipeline products market, download a sample report
Type 2 Diabetes Therapeutics Assessment by MoA
Number of Type 2 Diabetes Pipeline Products, by MoA
For more MoA insights on type 2 diabetes pipeline products market, download a sample report
Type 2 Diabetes Therapeutics Assessment by RoA
Number of Type 2 Diabetes Pipeline Products, by RoA
For more RoA insights on type 2 diabetes pipeline products market, download a sample report
Type 2 Diabetes Therapeutics Assessment by Molecule Type
Number of Type 2 Diabetes Pipeline Products, by Molecule Type
For more small molecule insights on type 2 diabetes pipeline products market, download a sample report
Type 2 Diabetes Pipeline Drugs Market Report Overview
What are the key targets in the type 2 diabetes pipeline drugs market?
The key targets in the type 2 diabetes pipeline products market are glucagon like peptide 1 receptor, insulin receptor, dipeptidyl peptidase 4, sodium/glucose cotransporter 2, adenosine monophosphate activated protein kinase, and others.
What are the key MoA in the type 2 diabetes pipeline drugs market?
The key mechanisms of action in the type 2 diabetes pipeline products market are glucagon like peptide 1 receptor agonist, insulin receptor agonist, dipeptidyl peptidase 4 inhibitor, sodium/glucose cotransporter 2 inhibitor, adenosine monophosphate activated protein kinase activator, others.
What are the key RoA in the type 2 diabetes pipeline drugs market?
The key routes of administration in the type 2 diabetes pipeline products market are oral, subcutaneous, parenteral, intravenous, transdermal, buccal, inhalational, sublingual, intraarticular, intracardiac, and others.
What are the key molecule types in the type 2 diabetes pipeline drugs market?
The key molecule types in the type 2 diabetes pipeline products market are small molecule, recombinant peptide, synthetic peptide, peptide, fusion protein, recombinant protein, biologic, monoclonal antibody, cell therapy, gene therapy, and others.
What are the key companies in the type 2 diabetes pipeline drugs market?
The major companies in the type 2 diabetes pipeline products market are Eli Lilly and Co, Novo Nordisk AS, Merck & Co Inc, Tonghua Dongbao Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Sihuan Pharmaceutical Holdings Group Ltd, AstraZeneca Plc, Diasome Pharmaceuticals Inc, Intarcia Therapeutics Inc, Thermalin Inc, Adocia SAS, Hanmi Pharmaceuticals Co Ltd, Pfizer Inc, Akston Biosciences Corp, Algiax Pharmaceuticals GmbH, Biocon Ltd, and others.
GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Mark Jephcott Head of PR EMEA mark.jephcott@globaldata.com cc: pr@globaldata.com
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.